{"transactions":[{"id":671136,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:02:38.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9730,"price":49.13,"value":478034.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":35.87,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":9730},"source":{"system":"sec-edgar","filing":"0001628280-26-059910","document":"wk-form4_1788296554.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059910/wk-form4_1788296554.xml","form_type":"4"}},{"id":671135,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:02:38.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10350,"price":52.67,"value":545134.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":32.33,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":10350},"source":{"system":"sec-edgar","filing":"0001628280-26-059910","document":"wk-form4_1788296554.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059910/wk-form4_1788296554.xml","form_type":"4"}},{"id":671134,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:02:38.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12500,"price":40.29,"value":503625.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":44.71,"expiration_date":"2034-06-07","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001628280-26-059910","document":"wk-form4_1788296554.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059910/wk-form4_1788296554.xml","form_type":"4"}},{"id":671133,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:02:38.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17500,"price":64.68,"value":1131900.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":20.32,"expiration_date":"2033-06-16","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001628280-26-059910","document":"wk-form4_1788296554.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059910/wk-form4_1788296554.xml","form_type":"4"}},{"id":671132,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:02:38.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17500,"price":66.71,"value":1167425.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":18.29,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001628280-26-059910","document":"wk-form4_1788296554.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059910/wk-form4_1788296554.xml","form_type":"4"}},{"id":671131,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:02:38.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17500,"price":64.77,"value":1133475.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":20.23,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001628280-26-059910","document":"wk-form4_1788296554.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059910/wk-form4_1788296554.xml","form_type":"4"}},{"id":671130,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:02:38.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12500,"price":61.77,"value":772125.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":23.23,"expiration_date":"2030-06-19","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001628280-26-059910","document":"wk-form4_1788296554.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059910/wk-form4_1788296554.xml","form_type":"4"}},{"id":671129,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:02:38.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12500,"price":61.76,"value":772000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":23.24,"expiration_date":"2029-06-21","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001628280-26-059910","document":"wk-form4_1788296554.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059910/wk-form4_1788296554.xml","form_type":"4"}},{"id":671128,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-01T21:02:38.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5925,"price":85,"value":503625.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a \"Company RSU\"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-26-059910","document":"wk-form4_1788296554.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059910/wk-form4_1788296554.xml","form_type":"4"}},{"id":671127,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-01T21:02:38.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":116146,"price":85,"value":9872410.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the \"Merger Agreement\"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the \"Company\"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (\"Parent\"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of September 1, 2026 (the \"Effective Time\"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the \"Company Common Stock\"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the \"Merger Consideration\")."}],"balance_after":5925,"source":{"system":"sec-edgar","filing":"0001628280-26-059910","document":"wk-form4_1788296554.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059910/wk-form4_1788296554.xml","form_type":"4"}},{"id":708351,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-07-16T20:34:25.000Z","date":"2026-07-15","kind":"grant","planned":false,"acquired":true,"shares":75,"price":82.62,"value":6196.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant."}],"balance_after":35563,"source":{"system":"sec-edgar","filing":"0001061983-26-000082","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198326000082/form4.xml","form_type":"4"}},{"id":730459,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T21:01:41.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":9730,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":9730,"derivative":{"exercise_price":35.87,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":9730},"source":{"system":"sec-edgar","filing":"0001628280-26-044710","document":"wk-form4_1782162098.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026044710/wk-form4_1782162098.xml","form_type":"4"}},{"id":730458,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T21:01:41.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":5925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the\nfirst anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through\nsuch vesting date."}],"balance_after":122071,"source":{"system":"sec-edgar","filing":"0001628280-26-044710","document":"wk-form4_1782162098.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026044710/wk-form4_1782162098.xml","form_type":"4"}},{"id":762473,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2026-05-27T23:08:10.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":4301,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4301,"derivative":{"exercise_price":77.15,"exercise_date":"2026-06-27","expiration_date":"2036-05-26","underlying":"Common Stock","underlying_shares":4301},"source":{"system":"sec-edgar","filing":"0001061983-26-000055","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198326000055/form4.xml","form_type":"4"}},{"id":762472,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-05-27T23:08:10.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":2851,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":35488,"source":{"system":"sec-edgar","filing":"0001061983-26-000055","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198326000055/form4.xml","form_type":"4"}},{"id":792533,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2026-05-05T20:20:48.000Z","date":"2026-05-05","kind":"exercise","planned":true,"acquired":false,"shares":4032,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable as to 4,032 shares divided into equal monthly installments such that the option shall be 100% vested on January 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":12.4,"exercise_date":"2017-02-03","expiration_date":"2027-01-03","underlying":"Common Stock","underlying_shares":4032},"source":{"system":"sec-edgar","filing":"0001061983-26-000050","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198326000050/form4.xml","form_type":"4"}},{"id":792532,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-05-05T20:20:48.000Z","date":"2026-05-05","kind":"sale","planned":true,"acquired":false,"shares":4032,"price":75,"value":302400.0,"ownership":{"direct":true},"balance_after":32637,"source":{"system":"sec-edgar","filing":"0001061983-26-000050","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198326000050/form4.xml","form_type":"4"}},{"id":792531,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-05-05T20:20:48.000Z","date":"2026-05-05","kind":"exercise","planned":true,"acquired":true,"shares":4032,"price":12.4,"value":49996.8,"ownership":{"direct":true},"balance_after":36669,"source":{"system":"sec-edgar","filing":"0001061983-26-000050","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198326000050/form4.xml","form_type":"4"}},{"id":808345,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-04-15T22:36:43.000Z","date":"2026-04-15","kind":"grant","planned":false,"acquired":true,"shares":95,"price":65.37,"value":6210.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares of common stock granted pursuant to Director Equity in Lieu of Cash Retainer Program. Shares are fully vested."}],"balance_after":32637,"source":{"system":"sec-edgar","filing":"0001061983-26-000041","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198326000041/form4.xml","form_type":"4"}},{"id":937670,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-01-16T21:20:42.000Z","date":"2026-01-15","kind":"grant","planned":false,"acquired":true,"shares":98,"price":63.44,"value":6217.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Fully vested shares of common stock received in lieu of cash retainer pursuant to Equity in Lieu of Cash Retainer Option available to members of our Board of Directors."}],"balance_after":32542,"source":{"system":"sec-edgar","filing":"0001061983-26-000007","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198326000007/form4.xml","form_type":"4"}},{"id":947020,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-07T01:00:11.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date."}],"balance_after":2500,"derivative":{"exercise_price":2.18,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001493152-26-000699","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226000699/ownership.xml","form_type":"4"}},{"id":960065,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2025-12-23T21:13:49.000Z","date":"2025-12-22","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":7.61,"exercise_date":"2016-06-18","expiration_date":"2026-05-18","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001061983-25-000051","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198325000051/form4.xml","form_type":"4"}},{"id":960064,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-12-23T21:13:49.000Z","date":"2025-12-22","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":66.14,"value":1322800.0,"ownership":{"direct":true},"balance_after":32444,"source":{"system":"sec-edgar","filing":"0001061983-25-000051","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198325000051/form4.xml","form_type":"4"}},{"id":960063,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-12-23T21:13:49.000Z","date":"2025-12-22","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":7.61,"value":152200.0,"ownership":{"direct":true},"balance_after":52444,"source":{"system":"sec-edgar","filing":"0001061983-25-000051","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198325000051/form4.xml","form_type":"4"}},{"id":1013371,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2025-10-27T21:59:36.000Z","date":"2025-10-27","kind":"exercise","planned":true,"acquired":false,"shares":4375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable as to 4,375 shares divided into equal monthly installments such that the option shall be 100% vested on January 4, 2017."}],"balance_after":0,"derivative":{"exercise_price":10,"exercise_date":"2016-02-04","expiration_date":"2026-01-04","underlying":"Common Stock","underlying_shares":4375},"source":{"system":"sec-edgar","filing":"0001061983-25-000026","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198325000026/form4.xml","form_type":"4"}},{"id":1013370,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-10-27T21:59:36.000Z","date":"2025-10-27","kind":"sale","planned":true,"acquired":false,"shares":4375,"price":58.68,"value":256725.0,"ownership":{"direct":true},"balance_after":32444,"source":{"system":"sec-edgar","filing":"0001061983-25-000026","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198325000026/form4.xml","form_type":"4"}},{"id":1013369,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-10-27T21:59:36.000Z","date":"2025-10-27","kind":"exercise","planned":true,"acquired":true,"shares":4375,"price":10,"value":43750.0,"ownership":{"direct":true},"balance_after":36819,"source":{"system":"sec-edgar","filing":"0001061983-25-000026","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198325000026/form4.xml","form_type":"4"}},{"id":1015449,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-10-21T16:22:38.000Z","date":"2025-10-15","kind":"grant","planned":false,"acquired":true,"shares":99,"price":62.8,"value":6217.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Director equity in lieu of cash retainer program."}],"balance_after":32444,"source":{"system":"sec-edgar","filing":"0001061983-25-000024","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198325000024/form4.xml","form_type":"4"}},{"id":1303562,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right  to Buy)","published_at":"2025-01-14T23:56:30.000Z","date":"2025-01-13","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date."}],"balance_after":5000,"derivative":{"exercise_price":1.38,"exercise_date":"2025-01-14","expiration_date":"2035-01-12","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001654954-25-000409","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495425000409/section16.xml","form_type":"4"}},{"id":1685679,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-06T02:01:15.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing January 4, 2024."}],"balance_after":10000,"derivative":{"exercise_price":0.6099,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001654954-24-000294","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424000294/section16.xml","form_type":"4"}},{"id":2140566,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-10-07T21:05:45.000Z","date":"2022-10-06","kind":"grant","acquired":true,"shares":20654,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On October 6, 2022, the Reporting Person was granted 20,654 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":62398,"source":{"system":"sec-edgar","filing":"0001654954-22-013525","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495422013525/section16.xml","form_type":"4"}},{"id":2210008,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-07-08T20:10:07.000Z","date":"2022-07-07","kind":"grant","acquired":true,"shares":18110,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 7, 2022, the Reporting Person was granted 18,110 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":41744,"source":{"system":"sec-edgar","filing":"0001654954-22-009453","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495422009453/section16.xml","form_type":"4"}},{"id":2300467,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-08T23:26:27.000Z","date":"2022-04-07","kind":"grant","acquired":true,"shares":10593,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 7, 2022, the Reporting Person was granted 10,593 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":15471,"source":{"system":"sec-edgar","filing":"0000905718-22-000572","document":"dermata_fm4apr72022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571822000572/dermata_fm4apr72022.xml","form_type":"4"}},{"id":2444441,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-06T00:07:27.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing January 3, 2022."}],"balance_after":5000,"derivative":{"exercise_price":1.88,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000905718-22-000046","document":"dermata_fm4jan32022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571822000046/dermata_fm4jan32022.xml","form_type":"4"}},{"id":2600570,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series 1d Preferred Stock","published_at":"2021-08-17T16:45:43.000Z","date":"2021-08-17","kind":"exercise","acquired":false,"shares":55078,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the \"IPO\"). The Series 1d Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the \"IPO\"). The Series 1d Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the \"IPO\"). The Series 1d Preferred Stock was convertible at any time and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8163},"source":{"system":"sec-edgar","filing":"0000905718-21-001104","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571821001104/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600569,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-17T16:45:43.000Z","date":"2021-08-17","kind":"exercise","acquired":true,"shares":8163,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the \"IPO\"). The Series 1d Preferred Stock was convertible at any time and had no expiration date."}],"balance_after":13041,"source":{"system":"sec-edgar","filing":"0000905718-21-001104","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571821001104/dermata_fm4aug172021.xml","form_type":"4"}}]}